West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$299.81 USD
+0.01 (0.00%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $299.98 +0.17 (0.06%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$299.81 USD
+0.01 (0.00%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $299.98 +0.17 (0.06%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Edwards Lifesciences (EW) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Improvement in Critical Care and Surgical Structural Heart businesses is expected to have contributed to Edwards Lifesciences' (EW) third-quarter results.
COVID Test Demand to Aid Quest Diagnostics (DGX) Q3 Earnings
by Zacks Equity Research
In terms of strategic acquisitions, Quest Diagnostics (DGX) is likely to have secured high returns in Q3 from the acquisition of Mercy's outreach laboratory services business.
The Zacks Analyst Blog Highlights: Abbott Laboratories, UnitedHealth, Quest, and West Pharmaceutical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, UnitedHealth, Quest, and West Pharmaceutical
Growing COVID-19 Testing Demand to Boost Abbott's (ABT) Q3 Earnings
by Zacks Equity Research
Through July to September, Abbott's (ABT) Diagnostic business is likely to have benefited from the significant surge in the new COVID-19 case counts.
Thermo Fisher (TMO) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Thermo Fisher's (TMO) recent launches within Chromatography and Mass Spectrometry like Thermo Scientific Orbitrap IQ-X Tribrid Mass Spectrometer should have contributed to its Q3 top line.
Why the Earnings Surprise Streak Could Continue for West Pharmaceutical (WST)
by Zacks Equity Research
West Pharmaceutical (WST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woe persists.
Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities
by Zacks Equity Research
Quest Diagnostics' (DGX) efforts to support AHA will boost innovative solutions like the Scholars programs, hypertension control and COVID-19 rapid response.
Catalent (CTLT) Expands Presence in Japan Via New Facility
by Zacks Equity Research
Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.
Medtronic (MDT) Sees Business Recovery Despite Volume Pressure
by Zacks Equity Research
According to Medtronic (MDT), healthcare systems are better prepared as vaccination rates continue to increase.
Veeva Systems' (VEEV) eConsent Solution Gets Adopted by Celerion
by Zacks Equity Research
Veeva Systems' (VEEV) solution gets adopted by Celerion in a bid to boost paperless clinical trials.
Here's Why You Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) owing to new product launches in the SDB market and strong sales of mask products.
Here's Why You Should Add DexCom (DXCM) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its slew of favorable coverage decisions for its G6 CGM System.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Here's Why You Should Retain LabCorp (LH) Stock For Now
by Zacks Equity Research
Strength in Drug Development business and new strategies to expand into high-growth markets raise optimism for LabCorp (LH).
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.
Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Invest in AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.
AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
Surmodics' (SRDX) Latest Sublime Catheter Expands Patient Pool
by Zacks Equity Research
Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.
Dexcom's (DXCM) G6 CGM System Gets Coverage in Manitoba
by Zacks Equity Research
Dexcom's (DXCM) CGM System is expected to simplify diabetes management due to increasing access to the life changing technology.
Reasons to Hold on to Inari Medical (NARI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inari Medical (NARI) owing to its focus on understanding the venous system and its commitment toward patient care.
Reasons to Hold on to Veeva Systems (VEEV) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of product launches and robust product adoptions.